Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. We started in 2019 with origins in field-leading AI and biophysics research out of Stanford's Pande Lab and a published collaboration with a top-five pharma company. We quickly assembled a team of seasoned biotech leaders and expert drug hunters, who have discovered and developed multiple FDA-approved medicines, to tightly integrate with our AI platform.
Since Genesis was founded, we've continued to pioneer state-of-the-art innovation in generative and predictive AI for small molecule drug discovery. Key proprietary innovations within our GEMS AI platform include Dynamic PotentialNet and our molecular generation engine. Dynamic PotentialNet integrates deep learning and molecular simulations to enable field-leading prediction of potency, selectivity, and ADMET. Our molecular generation engine allows Genesis scientists to search immense swaths of chemical space and offers significant advantages in addressing challenging and previously undruggable targets.
Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020).
The company is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego.